Latest Articles

Publication Date
All News Scientific
Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer - OncLive

Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer OncLive

Published: March 6, 2025, 2:32 p.m.
Read Full Article
Dr Wagar on Lenvatinib Plus Pembrolizumab vs Chemo in First-Line Advanced Endometrial Cancer - OncLive

Dr Wagar on Lenvatinib Plus Pembrolizumab vs Chemo in First-Line Advanced Endometrial Cancer OncLive

Published: March 5, 2025, 8:17 p.m.
Read Full Article
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial Nature.com

Published: March 5, 2025, 11:04 a.m.
Read Full Article
New endometriosis and pelvic pain clinic announced for Blue Mountains-Nepean - Blue Mountains Gazette

New endometriosis and pelvic pain clinic announced for Blue Mountains-Nepean Blue Mountains Gazette

Published: March 4, 2025, 12:43 a.m.
Read Full Article
The study on the clinical efficacy of endometrial receptivity analysis and influence factors of displaced window of implantation - Nature.com

The study on the clinical efficacy of endometrial receptivity analysis and influence factors of displaced window of implantation Nature.com

Published: March 1, 2025, 2:30 p.m.
Read Full Article
Business News | India's Declining Household Savings Amid Reduced FDI is Big Concern: Report - LatestLY

Business News | India's Declining Household Savings Amid Reduced FDI is Big Concern: Report LatestLY

Published: March 1, 2025, 4:28 a.m.
Read Full Article
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - BioMed Central

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central

Published: Feb. 28, 2025, 10:47 a.m.
Read Full Article
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - bmcwomenshealth.biomedcentral.com

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis bmcwomenshealth.biomedcentral.com

Published: Feb. 28, 2025, 10:47 a.m.
Read Full Article
Disgraced Triple M host Marty Sheargold disappears as big question goes unanswered - 7NEWS

Disgraced Triple M host Marty Sheargold disappears as big question goes unanswered 7NEWS

Published: Feb. 26, 2025, 8:58 a.m.
Read Full Article
Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial - Nature.com

Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial Nature.com

Published: Feb. 20, 2025, 9:18 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!